Slides
Page 1
Investor Presentation Q3FY26 23-01-2026 1
Page 2
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes “g” and “generic” used interchangeably indicate the generic versions of the named brand drugs. Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country. The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals. Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a healthcare professional. 2
Page 3
India Business Back on Strong Double-digit Growth Trajectory 1. Market data as per IQVIA Quarter ended Dec’25 | 2. Market data as per IQVIA week ending 26 th Dec 25 | 3. Market data as per IQVIA MAT Nov’25 Business Performance Snapshot Revenue EBITDA PAT INR 7,074 Cr INR 1,255 Cr INR 676 Cr $ 167 MnINR 3,457 Cr $ 112 Mn $ 104 Mn Respiratory outperformed the IPM1 growth by 400+ bps Albuterol ranked #1 in the overall U.S. Albuterol MDI market2 with a market share of 22% Ranked #2 in SA Prescription Market3 4th Consecutive Quarter with $ 100 Mn+ Revenue Q3FY26 One India North America One Africa Emerging Markets & Europe Q3FY26 18% of Revenue 3 10% of Revenue
Page 4
Financial Performance – Q3FY26 Revenue1 Break-up One India, 49% North America, 21% One Africa, 14% Emerging Markets & Europe, 13% API, 2% Others, 1% Revenue INR 7,074 Cr EBITDA INR 1,255 Cr Actuals (INR Cr) vs Q3 FY25 Total Revenue from Operations 7,074 0.02% EBITDA 1,255 -36.9% EBITDA % 17.7% PAT 676 -57.0% PAT % 9.6% Q3FY26 (Consolidated) R&D2 1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub -Saharan Africa and Cipla Global Access| 2. Opex including depreciation | 3. Total debt includes lease liabilities and borrowings| 4. Cash Balance includes current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | 5. Net Cash is Cash balance, net of Total Debt 7.0% of revenue 4 Balance Sheet Strength Dec-25 Total Debt3 Cash Balance4 Net Cash5 INR 489 Cr INR 10,718 Cr INR 10,229 Cr INR 494 Cr 37% (YoY)
Page 5
Branded Prescription ❖ Delivered a growth of 10% YoY ❖ Chronic mix improved to 62.3% in the IPM2 ❖ Key therapies like Respiratory, Anti-diabetes, Cardiac, Anti- infectives, and Urology outpaced the market2 growth Trade Generics ❖ Business delivered a strong growth during the quarter ❖ 2 Brands with TTM revenue of > INR 100 Cr and 5 Brands with TTM revenue of INR 50 Cr to INR 100 Cr ❖ 8 new launches in Q3 FY26, including entry into sexual wellness to expand therapy coverage Consumer Health ❖ Delivered a robust growth with anchor & transitioned brands continuing to grow bigger ❖ Sustained EBITDA trajectory ❖ Nicotex3, Omnigel4 and Cipladine4 ranked #1 in the market One India1 - Committed to Sustainable Progress and Enduring Impact 1. India includes Branded Prescription, Trade Generics and Consumer Health| 2. Market data as per IQVIA MAT Dec’25| 3. Market data as per IQVIA Mar’25 | 4. Market data as per AC Neilsen MAT Apr’25 5 Delivered a Revenue of INR 3,457 Cr in Q3 FY26
Page 6
India Rx - Strengthening Our Journey with Strategic Therapeutic Focus 1. Market data as per IQVIA MAT Dec’25 |2. Market data as per IQVIA Quarter ended Dec’25 22 Brands IPM1 Brands in Top 300 ranks Key Market Highlights IPM1 Brands with revenue > INR 100 Cr Steady Uptake in Key Therapies1 Growth (%) 6 Therapies With IPM1 Top 5 ranks 29 Brands #1 Foracort Biggest Brand in IPM1 6 Largest pharma company by volume (units) in market1 4 Brands added in the category of market1 revenue > INR 100 Cr YoY Respiratory supremacy, with Cipla's brands occupying all top 5 spots in the category1 30 Brands 13.4% 13.4% 15.2% 6.2% 10.7% 12.9% 10.2% 11.9% 4.7% 10.5% Cardiac Anti-diabetes Urology Anti-infectives Respiratory Market Growth Cipla Growth (16.6%)2 (12.4%)2
Page 7
One India - Strategic Alliances during the Quarter Pfizer Deal ❑ Cipla to exclusively market and distribute Pfizer’s key brands (Corex, Dolonex, Neksium, Dalacin C) in India ❑ Reinforces Cipla’s position in Acute therapy with trusted brands across Respiratory, Pain, Gastrointestinal, and Anti-infective segments ❑ Leverages Cipla’s deep distribution network to expand access and drive growth without upfront investment 7 Inzpera Acquisition ❑ Cipla acquires 100% stake in Inzpera Healthsciences, adding a differentiated paediatric and wellness portfolio ❑ Combines Inzpera’s portfolio with Cipla’s strong distribution network to accelerate growth and scalability ❑ Positions Cipla to capture rising demand in paediatric care, driving long-term value creation
Page 8
• Over 50 doctors have visited the facility to explore the center • Several patients diagnosed for various panels within the first 6 weeks of launch • Comprehensive panel testing for Asthma, COPD, and ILD conducted for the first time • Pulmonary rehabilitation is getting a significant attention • Smoker’s panel and CPET are attracting higher interest in Delhi Note - Model patient, pictures taken at the actual site 8 Launched India’s First Dedicated Lung Diagnostics & Wellness Center in Delhi
Page 9
9 Q3 FY26 - Global Consumer Wellness Franchise Skin Infection Pain Relief Hydration Nicotine Replacement Respi OTC Respi OTC One India One Africa Consumer Brands in One India Revenue: INR 442 Cr Consumer Brands in South Africa Revenue: ZAR 354 Mn 2 2 2 1 1. Market ranks as per IQVIA Mar’25 | 2. Market ranks as per AC Neilsen Apr’25 | Above numbers exclude sales of wellness brands through prescription channel Respi OTC Cold & Cough 2 Pain Management Pain Management
Page 10
North America – Adapting to Evolving Business Dynamics ➢ Albuterol ranked No. 1 with total market1 share at 22% (50 million+ inhaler units supplied to the U.S. market cumulatively) ➢ Lanreotide manufacturing is temporarily paused following USFDA observations at our partner Pharmathen’s facility; re-supply is expected in H1 FY27 ➢ gRevlimid had a small contribution in U.S. revenues this quarter ▪ Upcoming launches are expected to cushion this decline and provide long term growth Key Business Highlights 10 Pipeline Update 4 Respiratory Launches by FY27 MILESTONE4 Peptide launches by FY27 Including LiraglutideIncluding gAdvair 1. Market data as per IQVIA week ending 26th Dec’25 (No. 1 rank in overall U.S. Albuterol MDI market)
Page 11
97 23 38 9 23 3 66 1 11 7 2 2 Approved ANDAs & NDAs Tentatively Approved ANDAs & NDAs Under Approval ANDAs & NDAs Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs ANDA & NDA Portfolio & Pipeline (As on 31st December 2025) 1. PEPFAR approved ANDAs can be commercialised in the U.S. 179 Approved ANDAs & NDAs 49 Tentatively Approved ANDAs & NDAs 54 Under Approval ANDAs & NDAs 282 Total ANDAs & NDAs 1 11
Page 12
One Africa1 - South Africa Private Growing Faster than the Market 1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT Nov’25 In the prescription market2 SA Ranked #2 Across multiple therapies in Q3 FY26 4 new launches SA Key Highlights2 9 brands with MAT market revenue > 100 Mn ZAR Healthy performance across key therapies like CNS, Anti-infectives and Dermatology SA Private Revenue trendZAR Mn Highest number of brands in top 30 (7), top 50 (10) and top 100 (21) within generics segment 12 Market Segment 2 Rank Share Cipla Growth Market Growth South Africa Prescription 2 8.7% 8.7% 6.8% South Africa OTC 3 8.2% 2.2% 3.8% South Africa Overall 3 8.5% 6.3% 5.7% 67 68 24 20 10 9 14 15 Q3FY25 Q3FY26 SA Private SA Tender North Africa Others (SSA & CGA) 1,106 1,196 1,156 Q3FY24 Q3FY25 Q3FY26 ZAR Mn SA Private Revenue Trend
Page 13
98 104 Q3FY25 Q3FY26 Revenue Q3 FY26 - Emerging Markets & Europe and API Emerging Markets & Europe API 13 15 16 Q3FY25 Q3FY26 Revenue
Page 14
GLOBAL MANUFACTURING OPERATIONS ANAHATA : 2024-2028 Our ESG Roadmap : Near-Term & Long-Term Goals Pillar Aspects Near-Term 2030 Goals Environment Renewable Electricity share 80% for India manufacturing GHG Emission (Scope-1 & 2) 1. 30% Absolute reduction (Scope-1 energy based and Scope -2) from baseline of FY 2024 for Global Cipla 2. Build capacity infrastructure for green propellants used in MDI Water Neutrality Water Neutral for India manufacturing Zero waste to Landfill Maintain ZWL status for Cipla India and expand coverage for ZWL to overseas sites for USA and One Africa AMR One Antibiotic Product per Cipla India site certified as per AMR manufacturing standard Social Occupational Health & Safety Zero Fatality in manufacturing operations DEI Representation of women in Cipla Leadership Group at 20% or above, from a baseline year of FY 25 at 17% Governance Responsible Procurement Minimum 80% of our critical Indian suppliers to comply with Cipla ESG framework Pillar Aspect Long-Term 2050 Goal Environment Net Zero 2050 Signed for Net Zero by 2050 14
Page 15
Consolidated Profit and Loss Statement Summary Note : Figures have been rounded-off 15 Particulars Q3 FY26 Q3 FY25 Revenue from sale of products 6,963 6,962 Other operating income 112 111 Income from operations 7,074 7,073 Material cost 2,632 2,264 Employee benefits expense 1,325 1,198 Other expenses 1,862 1,622 Total expenses 5,819 5,084 Finance costs 14 15 Depreciation, impairment and amortization expense 278 280 Other income 206 222 Profit before exceptional items and tax 1,169 1,916 Exceptional Items 276 - Profit before tax 893 1,916 Tax expenses 219 332 Share of associate 0 -9 Profit for the period 674 1,575 Non-controlling interest -2 4 Profit for the period attributable to shareholders 676 1,571 INR Cr
Page 16
Consolidated Balance Sheet #Total debt includes lease liabilities and borrowings | * Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances |Figures have been rounded-off 16 Key Balance Sheet Items Dec-25 Dec-24 Equity 33,913 30,012 Total Debt# 489 466 Inventory 6,268 5,562 Cash and Cash Equivalents* 10,718 9,413 Trade Receivables 6,230 5,858 Trade Payables 3,254 2,764 Net Tangible Assets 7,213 6,372 Goodwill and Intangibles 5,679 4,984 INR Cr
Page 17
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 17